Karyopharm Therapeutics Inc. (KPTI) EPS Estimated At $-0.88

September 30, 2018 - By Jason Dias

Investors sentiment increased to 2.48 in Q2 2018. Its up 0.96, from 1.52 in 2018Q1. It increased, as 10 investors sold Karyopharm Therapeutics Inc. shares while 17 reduced holdings. 31 funds opened positions while 36 raised stakes. 41.97 million shares or 39.32% more from 30.12 million shares in 2018Q1 were reported.
Legal General Public Ltd Company stated it has 7,705 shares. Teachers Retirement Of The State Of Kentucky invested in 0% or 18,700 shares. Vanguard Grp Inc Incorporated holds 0% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 2.49M shares. State Of Wisconsin Invest Board has invested 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Citigroup owns 51,963 shares or 0% of their US portfolio. Manufacturers Life Ins The owns 35,164 shares. Moore Cap Ltd Partnership has invested 0.06% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Daiwa Gp Inc Inc holds 261 shares. 25,900 are held by Strs Ohio. Aqr Capital Ltd Co has 19,153 shares for 0% of their portfolio. Morgan Stanley invested in 108,271 shares. Tower Rech Ltd Liability Corp (Trc) stated it has 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Knott David M holds 0.2% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 32,000 shares. State Board Of Administration Of Florida Retirement Systems stated it has 16,349 shares or 0% of all its holdings. Art Advsrs Limited Com holds 0.07% or 107,119 shares in its portfolio.

Since April 9, 2018, it had 0 insider purchases, and 35 selling transactions for $22.69 million activity. $1.50M worth of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was sold by Chione Ltd. Kauffman Michael sold $174,568 worth of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) on Monday, August 20. The insider Mirza Mansoor Raza sold 2,500 shares worth $52,500. $36,024 worth of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was sold by Primiano Christopher Brett on Thursday, May 10.

Analysts expect Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to report $-0.88 EPS on November, 1.They anticipate $0.23 EPS change or 35.38 % from last quarter’s $-0.65 EPS. After having $-0.60 EPS previously, Karyopharm Therapeutics Inc.’s analysts see 46.67 % EPS growth. The stock decreased 0.41% or $0.07 during the last trading session, reaching $17.03. About 477,191 shares traded or 9.06% up from the average. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has risen 75.47% since September 30, 2017 and is uptrending. It has outperformed by 59.85% the S&P500.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Ratings Coverage

Among 6 analysts covering Karyopharm Therapeutics (NASDAQ:KPTI), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Karyopharm Therapeutics had 6 analyst reports since April 10, 2018 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, May 15 by Canaccord Genuity. The rating was maintained by Cantor Fitzgerald on Monday, April 30 with “Buy”. The company was maintained on Tuesday, May 1 by Leerink Swann. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) earned “Buy” rating by Jefferies on Wednesday, April 25. JP Morgan maintained the stock with “Overweight” rating in Tuesday, April 10 report. As per Thursday, May 24, the company rating was downgraded by Wedbush.

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The company has market cap of $1.03 billion. The Company’s lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. It currently has negative earnings. The firm is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin's lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases.

More notable recent Karyopharm Therapeutics Inc. (NASDAQ:KPTI) news were published by: Seekingalpha.com which released: “Karyopharm Therapeutics: Can The Rally Continue?” on September 17, 2018, also Seekingalpha.com with their article: “Stocks To Watch: Strap In For Q3” published on September 29, 2018, Nasdaq.com published: “Selinexor Clinical Data to be Presented at the 21st Annual Meeting of the Chinese Society of Clinical Oncology” on September 20, 2018. More interesting news about Karyopharm Therapeutics Inc. (NASDAQ:KPTI) were released by: Nasdaq.com and their article: “Phase 2b STORM Data Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma Presented at the …” published on September 13, 2018 as well as Globenewswire.com‘s news article titled: “Karyopharm to Participate in Upcoming Investor Conferences” with publication date: September 22, 2018.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: